In addition, allosteric feedback inhibition by purine nucleotides of phosphoribosyl pyrophosphate amidotransferase, the rate-limiting enzyme in the purine de novo pathway, accounts for the decreased total purine excretion that is observed in patients with XOR deficiency and those taking XOR inhibitors (11, 41). Here, XDH is linked to xanthinuria type I.